CAR T Cell Therapy, short for chimeric antigen receptor T cell therapy, represents a groundbreaking approach in the field of cancer treatment. This innovative immunotherapy harnesses the power of a patient's own immune system to combat cancer cells. With its remarkable success in treating certain types of leukemia and lymphoma, CAR T cell therapy has emerged as a game-changer, offering new hope to patients who have exhausted conventional treatment options. In this article, we will explore the concept of CAR T cell therapy, its mechanism of action, successes, challenges, and its potential for the future of cancer care.

CAR T Cell Therapy involves reprogramming a patient's T cells, a type of white blood cell, to target and eliminate cancer cells. The process begins by collecting the patient's T cells through a blood sample. These T cells are then genetically modified in a laboratory to express a chimeric antigen receptor (CAR) on their surface. The CAR is designed to recognize specific proteins, known as antigens, that are present on the surface of cancer cells.